Abstract
While treatment with aromatase inhibitors have improved outcome as compared to tamoxifen in advanced as well as in adjuvant breast cancer therapy, similar to what has been recorded with tamoxifen as well as for oophorectomy in premenopausal women, the reduction in risk for a relapse as well as breast cancer death in the adjuvant setting is less than 50 %. Thus, many patients reveal resistance to aromatase inhibitor therapy even in the early setting. As for metastatic disease, endocrine therapy with aromatase inhibitors, like other forms of endocrine treatment and chemotherapy, remains palliative. Looking at plasma estrogen levels as well as total body aromatization, patients treated with third-generation aromatase inhibitors (anastrozole, letrozole and exemestane) all seem to get profound plasma estrogen suppression as well as effective total body aromatase inhibition. As for studies assessing intratumour estrogen levels, they all point in the same direction; so far, there is no evidence indicating lack of tissue estrogen suppression among individual patients. Important, these findings do not exclude the possibility that in some patients intratumour aromatase to some degree may escape inhibition; however, due to rapid equilibrium with the plasma pool, such a phenomenon most likely should have limited effect on intratumoural estrogen levels.
Keywords
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- AIs:
-
Aromatase Inhibitors
- ER:
-
Estrogen Receptor
- E2:
-
Estradiol E1, Estrone
- E1S:
-
Estrone Sulfate
- HR:
-
Hazards Ratio
References
Mouridsen H, Gershanovich M, Sun Y, Pérez-Carrión R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jänicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 2001;19:2596–606.
Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28(3):509–18.
Davies C, Godwin J, Gray R, Clarke M, Darby S, McGale P, Wang YC, Peto R, Pan HC, Cutter D, Taylor C, Ingle J. Ebctcg. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84.
Group E B C T C. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet. 1996;348:1189–1196.
Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, Bishop H, Ellis I, Larsimont D, Sasano H, Carder P, Cussac A, Knox F, Speirs V, Forbes J, Buzdar A. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial. J Clin Oncol. 2008;26:1059–65.
Lønning PE. Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? Eur J Cancer. 2009;45(4):527–35.
Lønning PE. Additive endocrine therapy for advanced breast cancer—back to the future. Acta Oncol. 2009;48(8):1092–101.
Lønning PE, Hall K, Aakvaag A, Lien EA. Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Res. 1992;52(17):4719–23.
Lønning PE, Johannessen DC, Lien EA, Ekse D, Fotsis T, Adlercreutz H. Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients. J Steroid Biochem Mol Biol. 1995;52:491–6.
Helle SI, Anker G, Tally M, Hall K, Lønning PE. Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, pro-IGF-IIE, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-3 in breast cancer patients. J Steroid Biochem Mol Biol. 1996;57:167–71.
Geisler J, Haarstad H, Gundersen S, Raabe N, Kvinnsland S, Lønning PE. Influence of treatment with the anti-oestrogen 3-hydroxytamoxifen (droloxifene) on plasma sex hormone levels in postmenopausal patients with breast cancer. J Endocrinol. 1995;146:359–63.
Geisler J, Ekse D, Hösch S, Lønning PE. Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients. J Steroid Biochem Mol Biol. 1995;55:193–5.
Lønning PE. The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Ann Oncol. 2011;22(3):503–14.
Lønning PE, Dowsett M, Powles TJ. Postmenopausal estrogen synthesis and metabolism: Alterations caused by aromatase inhibitors used for the treatment of breast cancer. J Steroid Biochem. 1990;35:355–66.
Sluijmer AV, Heineman MA, Jong FHD, Evers JLH. Endocrine activity of the postmenopausal ovary: The effects of pituitary down-regulation and oophorectomy. J Clin Endocrinol Metab. 1995;80:2163–2167.
Couzinet B, Meduri G, Lecce MG, Young J, Brailly S, Loosfelt H, Milgrom E, Schaison G. The postmenopausal ovary is not a major androgen-producing gland. J Clin Endocrinol Metab. 2001;86:5060–6.
Dowsett M, Cantwell B, Lal A, Jeffcoate SL, Harris AL. Suppression of postmenopausal ovarian steroidogenesis with the luteinizing hormone-releasing hormone agonist goserelin. J Clin Endocrinol Metab. 1988;66:672–7.
van Landeghem AJJ, Poortman J, Nabuurs M, Thijssen JHH. Endogenous concentration and subcellular distribution of estrogens in normal and malignant breast tissue. Cancer Res. 1985;45:2900–4.
Edery M, Goussard J, Dehennin L, Scholler R, Reiffsteck J, Drosdowsky MA. Endogenous oestradiol-17ß concentration in breast tumours determined by mass fragmnentography and by radioimmunoassay: relationship to receptor content. Eur J Cancer. 1980;17:115–20.
Vermeulen A, Deslypere JP, Paridaens R, Leclerco G, Roy F, Heuson JC. Aromatase, 17ß-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women. Eur J Cancer Clin Oncol. 1986;22(4):515–25.
Miller WR, Telford J, Love C, Leonard RCF, Hillier S, Gundacker H, Smith H, Dixon JM. Effects of letrozole as primary medical therapy on in situ oestrogen synthesis and endogenous oestrogen levels within the breast. Breast. 1998;7:273–6.
Geisler J, Detre S, Berntsen H, Ottestad L, Lindtjørn B, Dowsett M, Lønning PE. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin Cancer Res. 2001;7:1230–6.
Geisler J, Helle H, Ekse D, Duong NK, Evans DB, Nordbo Y, Aas T, Lonning PE. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Clin Cancer Res. 2008;14(19):6330–5.
Shibuya R, Suzuki T, Miki Y, Yoshida K, Moriya T, Ono K, Akahira J, Ishida T, Hirakawa H, Evans DB, Sasano H. Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast. Endocr Relat Cancer. 2008;15(1):113–24.
Suzuki T, Miki Y, Akahira JI, Moriya T, Ohuchi N, Sasano H. Aromatase in human breast carcinoma as a key regulator of intratumoral sex steroid concentrations. Endocr J. 2008;55(3):455–63.
Ghosh D, Griswold J, Erman M, Pangborn W. Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature. 2009;457(7226):219–23.
Bulun SE, Sebastian S, Takayama K, Suzuki T, Sasano H, Shozu M. The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters. J Steroid Biochem Molec Biol. 2003;86(3–5):219–24.
Agarwal VR, Bulun SE, Leitch M, Rohrich R, Simpson ER. Use of alternative promoters to express the aromatase cytochrome p450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. J Clin Endocrinol Metab. 1996;81(11):3843–9.
Clyne CD, Kovacic A, Speed CJ, Zhou J, Pezzi V, Simpson ER. Regulation of aromatase expression by the nuclear receptor LRH-1 in adipose tissue. Mol Cell Endocrinol. 2004;215(1–2):39–44.
Zhou J, Suzuki T, Kovacic A, Saito R, Miki Y, Ishida T, Moriya T, Simpson ER, Sasano H, Clyne CD. Interactions between prostaglandin E-2, liver receptor homologue-1, and aromatase in breast cancer. Cancer Res. 2005;65(2):657–63.
Mendelson CR, Jiang B, Shelton JM, Richardson JA, Hinshelwood MM. Transcriptional regulation of aromatase in placenta and ovary. J Steroid Biochem Mol Biol. 2005;95(1–5):25–33.
Lønning PE, Helle H, Duong NK, Ekse D, Aas T, Geisler J. Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. J Steroid Biochem Mol Biol. 2009;117:31–41.
Haynes BP, Straume AH, Geisler J, A’Hern R, Helle H, Smith IE, Lønning PE, Dowsett M. Intratumoral estrogen disposition in breast cancer. Clin Cancer Res. 2010;16(6):1790–801.
Dorgan JF, Longcope C, Stanczyk FZ, Stephenson HE, Hoover RN. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1999;91(4):380–1.
Lønning PE, Helle SI, Johannessen DC, Ekse D, Adlercreutz H. Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer. Breast Cancer Res Treat. 1996;39:335–41.
Dunbier AK, Anderson H, Ghazoui Z, Folkerd EJ, A’Hern R, Crowder RJ, Hoog J, Smith IE, Osin P, Nerurkar A, Parker JS, Perou CM, Ellis MJ, Dowsett M. Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women. J Clin Oncol. 2010;28(7):1161–7.
Lønning PE, Haynes BP, Straume AH, Dunbier A, Helle H, Knappskog S, Dowsett M. Exploring breast cancer estrogen disposition: the basis for endocrine manipulation. Clin Cancer Res. 2011;17(15):4948–58.
Folkerd EJ, Lønning PE, Dowsett M. Interpreting plasma estrogen levels in breast cancer: caution needed. J Clin Oncol. 2014;32(14):1396– + .
Lønning PE, Helle H, Duong NK, Ekse D, Aas T, Geisler J. Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. J Steroid Biochem Mol Biol. 2009;117(1–3):31–41.
Santen RJ, Demers LM, Adlercreutz H, Harvey H, Santner S, Sanders S, Lipton A. Inhibition of aromatase with CGS 16949a in postmenopausal women. J Clin Endocrinol Metab. 1989;68(1):99–106.
Demers LM, Lipton A, Harvey HA, Kambic KB, Grossberg H, Brady C, Santen RJ. The efficacy of CGS 20267 in suppressing estrogen biosynthesis in patients with advanced stage breast cancer. J Steroid Biochem Mol Biol. 1993;44:687–91.
Dowsett M, Goss PE, Powles TJ, Hutchinson G, Brodie AMH, Jeffcoate SL, Coombes RC. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res. 1987;47:1957–61.
Dowsett M, Cunningham DC, Stein RC, Evans S, Dehennin L, Hedley A, Coombes RC. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res. 1989;49:1306–12.
Dowsett M, Stein RC, Mehta A, Coombes RC. Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clin Endocrinol. 1990;32:623–34.
Dowsett M, MacNeill F, Mehta A, Newton C, Haynes B, Jones A, Jarman M, Lonning P, Powles TJ, Coombes RC. Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione (‘pyridoglutethimide’) in postmenopausal breast cancer patients. Br J Cancer. 1991;64(5):887–94.
Dowsett M, Mehta A, King N, Smith IE, Powles TJ, Stein RC, Coombes RC. An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients. Eur J Cancer. 1992;28:415–20.
Iveson TJ, Smith IE, Ahern J, Smithers DA, Trunet PF, Dowsett M. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res. 1993;53:266–70.
Dixon JM, Renshaw L, Young O, Murray J, Macaskill EJ, McHugh M, Folkerd E, Cameron DA, A’Hern RP, Dowsett M. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol. 2008;26(10):1671–6.
Lønning PE, Ekse D. A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors. J Steroid Biochem Mol Biol. 1995;55(3/4):409–12.
Geisler J, Ekse D, Helle H, Duong N, Lønning P. An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples. J Steroid Biochem Molec Biol. 2008;109:90–5.
Geisler J, Haynes B, Anker G, Dowsett M, Lønning PE. Influence of letrozole (Femara) and anastrozole (Arimidex) on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over-designed study. J Clin Oncol. 2002;20:751–7.
Geisler J, Helle H, Ekse D, Duong NK, Evans DB, Nordbo Y, Aas T, Lønning PE. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. Clin Cancer Res. 2008;14(19):6330–5.
Johannessen DC, Engan T, Salle ED, Zurlo MG, Paolini J, Ornati G, Piscitelli G, Kvinnsland S, Lønning PE. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res. 1997;3:1101–1108.
Pfeiler G, Konigsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer CF, Postlberger S, Steger GG, Seifert M, Dubsky P, Taucher S, Samonigg H, Bjelic-Radisic V, Greil R, Marth C, Gnant M. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol. 2011;29(19):2653–9.
Sestak I, Distler W, Forbes JF, Dowsett M, Howell A, Cuzick J. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol. 2010;28(21):3411–5.
Ewertz M, Gray KP, Regan MM, Ejlertsen B, Price KN, Thurlimann B, Bonnefoi H, Forbes JF, Paridaens RJ, Rabaglio M, Gelber RD, Colleoni M, Lang I, Smith IE, Coates AS, Goldhirsch A, Mouridsen HT. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. J Clin Oncol. 2012;30(32):3967–75.
Folkerd EJ, Dixon JM, Renshaw L, A’Hern RP, Dowsett M. Suppression of plasma estrogen levels by letrozole and anastrozole is related to body mass index in patients with breast cancer. J Clin Oncol. 2012;30(24):2977–80.
Lønning PE, Haynes B, Dowsett M. Relationship of body mass index with aromatisation and plasma and tissue estrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors. Eur J Cancer. 2014;50:1055–64.
Santen RJ, Santner SJ, TilsenMallett N, Rosen HR, Samojlik E, Veldhuis JD. In vivo and in vitro pharmacological studies of aminoglutethimide as an aromatase inhibitor. Cancer Res. 1982;Suppl. 42:3353s–3359s.
Lønning PE, Skulstad P, Sunde A, Thorsen T. Separation of urinary metabolites of radiolabelled estrogens in man by HPLC. J. Steroid Biochem. 1989;32:91–7.
Lønning PE, Jacobs S, Jones A, Haynes B, Powles T, Dowsett M. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. Br J Cancer. 1991;63:789–93.
Jones AL, MacNeill F, Jacobs S, Lønning PE, Dowsett M, Powles TJ. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. Eur J Cancer. 1992;28A:1712–6.
MacNeill FA, Jones AL, Jacobs S, Lønning PE, Powles TJ, Dowsett M. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br J Cancer. 1992;66(4):692–7.
MacNeill FA, Jacobs S, Dowsett M, Lønning PE, Powles TJ. The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients. Cancer Chemother Pharmacol. 1995;36(3):249–54.
MacNeill FA, Jacobs S, Lønning PE, Powles TJ, Dowsett M. Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression. Br J Cancer. 1994;69:1171–5.
Geisler J, King N, Dowsett M, Ottestad L, Lundgren S, Walton P, Kormeset PO, Lønning PE. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer. 1996;74(8):1286–91.
Geisler J, King N, Anker G, Ornati G, Di Salle E, Lønning PE, Dowsett M. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res. 1998;4(9):2089–93.
Lønning PE. Aromatase inhibitors in breast cancer. End-Rel Cancer. 2004;11:179–89.
Miller WR. Aromatase activity in breast tissue. J Steroid Biochem Molec Biol. 1991;39(5b):783–90.
Santner SJ, Leszcynski D, Wright C, Manni A, Feil PD, Santen RJ. Estrone sulfate: a potential source of estradiol in human breast cancer tissue. Breast Cancer Res Treat. 1986;7:35–44.
Miller WR. Importance of intratumour aromatase, and its susceptibility to inhibitors. In: Dowsett M editor. Aromatase inhibition—then, now and tomorrow. London: Partenon Publishing Group; 1994. p. 43–53.
Geisler J, Berntsen H, Lønning P. A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue. J Steroid Biochem Molec Biol. 2000;72:259–64.
Chetrite GS, Cortes-Prieto J, Philippe JC, Wright F, Pasqualini JR. Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J Steroid Biochem Mol Biol. 2000;72(1–2):23–7.
Larionov AA, Berstein LM, Miller WR. Local uptake and synthesis of oestrone in normal and malignant postmenopausal breast tissues. J Steroid Biochem Mol Biol. 2002;81(1):57–64.
Conflict of Interest
No potential conflicts of interest were disclosed.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Lønning, P.E. (2015). Ineffective Inhibition of Aromatase: A Cause for AI Resistance?. In: Larionov, A. (eds) Resistance to Aromatase Inhibitors in Breast Cancer. Resistance to Targeted Anti-Cancer Therapeutics, vol 8. Springer, Cham. https://doi.org/10.1007/978-3-319-17972-8_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-17972-8_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-17971-1
Online ISBN: 978-3-319-17972-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)